在亚组分析中应考虑血液透析剂量和频率。
Hemodialysis dose and frequency should be considered in subgroup analysis.
机构信息
Department of Cardiology, The First People's Hospital of Chenzhou, Chenzhou, 423000, Hunan, China.
Department of Cardiology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
出版信息
Cardiovasc Diabetol. 2024 Nov 19;23(1):416. doi: 10.1186/s12933-024-02482-x.
The article by Wang et al. titled "Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis" demonstrated that new SGLT-2i use in T2DM patients at the onset of dialysis was associated with a reduced long-term risk of all-cause mortality and MACE over a median follow-up duration of 2.0 years. However, the hemodialysis dose and frequency, which are significant confounding factors, were not included in the study's subgroup analysis. We raise concerns about this limitation, which may affect the study's findings.
Wang 等人的文章题为“在开始透析的 2 型糖尿病患者中探索 SGLT-2 抑制剂的死亡率和心血管结局：全球健康联合会网络分析”，表明新的 SGLT-2i 在开始透析时用于 2 型糖尿病患者与在中位随访 2.0 年内全因死亡率和 MACE 的长期风险降低相关。然而，血液透析剂量和频率这两个重要的混杂因素并未包含在研究的亚组分析中。我们对这一局限性表示关注，因为它可能会影响研究结果。
Zotero 插件